ATE508191T1 - Adipozytenspezifische konstrukte und verfahren zur hemmung der expression von blutplättchen-typ- 12-lipoxygenase - Google Patents

Adipozytenspezifische konstrukte und verfahren zur hemmung der expression von blutplättchen-typ- 12-lipoxygenase

Info

Publication number
ATE508191T1
ATE508191T1 AT07827307T AT07827307T ATE508191T1 AT E508191 T1 ATE508191 T1 AT E508191T1 AT 07827307 T AT07827307 T AT 07827307T AT 07827307 T AT07827307 T AT 07827307T AT E508191 T1 ATE508191 T1 AT E508191T1
Authority
AT
Austria
Prior art keywords
methods
expression
platelet
type
lipoxygenase
Prior art date
Application number
AT07827307T
Other languages
English (en)
Inventor
Gary Weisinger
Rona Limor
Naftali Stern
Original Assignee
Medical Res And Infrastructure Fund Of The Tel Aviv Sourasky Medical Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Res And Infrastructure Fund Of The Tel Aviv Sourasky Medical Ct filed Critical Medical Res And Infrastructure Fund Of The Tel Aviv Sourasky Medical Ct
Application granted granted Critical
Publication of ATE508191T1 publication Critical patent/ATE508191T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT07827307T 2006-11-01 2007-11-01 Adipozytenspezifische konstrukte und verfahren zur hemmung der expression von blutplättchen-typ- 12-lipoxygenase ATE508191T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85573606P 2006-11-01 2006-11-01
PCT/IL2007/001333 WO2008053487A2 (en) 2006-11-01 2007-11-01 Adipocyte-specific constructs and methods for inhibiting platelet-type 12 lipoxygenase expression

Publications (1)

Publication Number Publication Date
ATE508191T1 true ATE508191T1 (de) 2011-05-15

Family

ID=39251348

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07827307T ATE508191T1 (de) 2006-11-01 2007-11-01 Adipozytenspezifische konstrukte und verfahren zur hemmung der expression von blutplättchen-typ- 12-lipoxygenase

Country Status (7)

Country Link
US (3) US9279127B2 (de)
EP (1) EP2078079B1 (de)
AT (1) ATE508191T1 (de)
CA (1) CA2667971C (de)
DE (1) DE602007014389D1 (de)
IL (1) IL198421A (de)
WO (1) WO2008053487A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA33933B1 (fr) 2010-01-22 2013-01-02 Bayer Ip Gmbh Combinaisons de principes actifs acaricides et/ou insecticides
CN103717076B (zh) 2011-08-10 2016-04-13 拜耳知识产权股份有限公司 含有特定特特拉姆酸衍生物的活性化合物组合物
US20140178456A1 (en) * 2012-08-30 2014-06-26 Udaya Sankar Devanaboyina Methods and compositions for treating type 2 diabetes and related conditions
EP3449001B1 (de) 2016-04-29 2021-12-08 Aptamir Therapeutics, Inc. Hemmung von mir-22-mirna durch apt-110
WO2018218185A1 (en) * 2017-05-26 2018-11-29 Marshall University Research Corporation EXPRESSION VECTORS AND RELATED METHODS OF DELIVERY OF Na/K ATPASE/Src RECEPTOR COMPLEX ANTAGONISTS
JP7378580B2 (ja) * 2020-03-24 2023-11-13 平田機工株式会社 観察用ホルダ、観察装置、観察用チップおよびその製造方法
CA3200227A1 (en) * 2020-11-25 2022-06-02 Alexandra Sophie DE BOER Adipogenic cell compositions and methods
EP4655408A2 (de) * 2023-01-27 2025-12-03 Oisin Biotechnologies, Inc. Zusammensetzungen, systeme und verfahren zur reduzierung von fettgewebe

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
JP2507895B2 (ja) 1989-12-19 1996-06-19 工業技術院長 リボザイムの新規合成系
EP0653488B1 (de) 1992-07-02 2003-04-09 Sankyo Company Limited Haarnadelförmiges ribozym
US6191169B1 (en) * 1992-08-28 2001-02-20 City Of Hope Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states
US5807718A (en) 1994-12-02 1998-09-15 The Scripps Research Institute Enzymatic DNA molecules
US5545729A (en) 1994-12-22 1996-08-13 Hybridon, Inc. Stabilized ribozyme analogs
US20050261485A1 (en) 1996-05-23 2005-11-24 Toagosei Co., Ltd., A Japan Corporation Method of producing antisense oligonucleotide
US5861268A (en) * 1996-05-23 1999-01-19 Biomide Investment Limited Partnership Method for induction of tumor cell apoptosis with chemical inhibitors targeted to 12-lipoxygenase
US5869037A (en) * 1996-06-26 1999-02-09 Cornell Research Foundation, Inc. Adenoviral-mediated gene transfer to adipocytes
EP0856579A1 (de) 1997-01-31 1998-08-05 BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH Ein Verfahren zur Zubereitung von Antisense Oligonukleotiden
AU8280798A (en) 1997-07-03 1999-01-25 Thomas Jefferson University An improved method for design and selection of efficacious antisense oligonucleotides
WO2006094406A1 (en) 2005-03-11 2006-09-14 Sarissa Inc. Antisense oligonucleotides targeted to the coding region of thymidylate synthase and uses thereof
CA2303935A1 (en) * 1997-10-15 1999-04-22 City Of Hope 12(s)-hete receptor blockers
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AU3905599A (en) 1998-05-20 1999-12-06 City Of Hope Method of treating or preventing abnormal cardiac cell growth by inhibiting the 12-lipoxygenase pathway
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
AU779411B2 (en) * 1999-02-12 2005-01-20 Serono Genetics Institute S.A. Biallelic markers derived from genomic regions carrying genes involved in arachidonic acid metabolism
US6110462A (en) 1999-03-03 2000-08-29 The Scripps Research Institute Enzymatic DNA molecules that contain modified nucleotides
FR2790757B1 (fr) 1999-03-09 2003-08-01 Bioalliance Pharma Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant.
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
US6485976B1 (en) 1999-04-30 2002-11-26 City Of Hope Use of adeno-associated virus (AAV) to deliver genes
RU2164944C1 (ru) 1999-12-09 2001-04-10 Институт молекулярной биологии им. В.А. Энгельгардта РАН Способ изменения генетических свойств организма
NZ522045A (en) 2000-03-30 2007-05-31 Whitehead Biomedical Inst RNA sequence-specific mediators of RNA interference
AU5137901A (en) 2000-04-06 2001-10-23 Coastside Res Method to inhibit lipoxygenase and cancer cell proliferation
IL155991A0 (en) 2000-12-01 2003-12-23 Max Planck Gesellschaft Rna interference mediating small rna molecules
US20060217331A1 (en) 2001-05-18 2006-09-28 Sirna Therapeutics, Inc. Chemically modified double stranded nucleic acid molecules that mediate RNA interference
AU2003281867A1 (en) * 2002-03-28 2004-02-23 University Of Florida Antisense nucleic acids
AU2003239226A1 (en) 2002-06-11 2003-12-22 Isis Pharmaceuticals, Inc. METHODS FOR BLOCKING ADIPOCYTE DIFFERENTIATION AND TRIGLYCERIDE ACCUMULATION WITH INTERLEUKIN 12 p35 INHIBITORS
US20060154882A1 (en) 2002-06-11 2006-07-13 Marcusson Eric G Methods for blocking adipocyte differentiation and triglyceride accumulation with g-alpha-i3 inhibitors
US20060122131A1 (en) 2002-06-11 2006-06-08 Marcusson Eric G Methods for blocking adipocyte differentiation and triglyceride accumulation with transcription factor dp-1 inhibitors
AU2003273351A1 (en) 2002-09-24 2004-04-19 Isis Pharmaceutical, Inc. Methods for blocking adipocyte differentiation and triglyceride accumulation with dual-specificity tyrosine- (y) - phosphorylation regulated kinase 4 (dyrk4) inhibitors
US20040147469A1 (en) 2002-11-01 2004-07-29 Case Western Reserve University Methods of inhibiting glial scar formation
AU2003292822A1 (en) * 2002-12-26 2004-07-22 Yuji Matsuzawa Adiponectin promoter and use thereof
JP2006520611A (ja) 2003-03-05 2006-09-14 セネスコ テクノロジーズ，インコーポレイティド ｅＩＦ−５Ａ１の発現を抑制するための、アンチセンス・オリゴヌクレオチド又はｓｉＲＮＡの使用
JP4742032B2 (ja) * 2004-03-31 2011-08-10 株式会社東京大学Ｔｌｏ アディポネクチン発現誘導剤およびその利用
US20060078902A1 (en) 2004-04-15 2006-04-13 Michaeline Bunting Method and compositions for RNA interference
WO2006039285A2 (en) * 2004-09-30 2006-04-13 The University Of Georgia Research Foundation, Inc. Compositions and methods for inducing adipose tissue cell death
US7608277B2 (en) 2004-12-01 2009-10-27 Gene Therapy Systems, Inc. Tuberculosis nucleic acids, polypeptides and immunogenic compositions
JP2008521909A (ja) 2004-12-02 2008-06-26 ビー−ブリッジ インターナショナル，インコーポレーテッド 短鎖干渉ｒｎａ、アンチセンスポリヌクレオチド、および他のハイブリッド形成化ポリヌクレオチドの設計方法
US20100150885A1 (en) * 2005-06-01 2010-06-17 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis

Also Published As

Publication number Publication date
EP2078079A2 (de) 2009-07-15
WO2008053487A2 (en) 2008-05-08
US9663790B2 (en) 2017-05-30
IL198421A (en) 2014-04-30
CA2667971C (en) 2017-04-18
DE602007014389D1 (de) 2011-06-16
US20110038923A1 (en) 2011-02-17
US20150191734A1 (en) 2015-07-09
IL198421A0 (en) 2011-08-01
EP2078079B1 (de) 2011-05-04
CA2667971A1 (en) 2008-05-08
US9279127B2 (en) 2016-03-08
US20170327827A1 (en) 2017-11-16
WO2008053487A3 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
ATE508191T1 (de) Adipozytenspezifische konstrukte und verfahren zur hemmung der expression von blutplättchen-typ- 12-lipoxygenase
MX2022009707A (es) Vacunas de dominio de arnm contra el sars-cov-2.
ZA201902226B (en) Aav treatment of huntington's disease
EA201290572A1 (ru) Растения, устойчивые к гербицидам - ингибиторам hppd
EA201290560A1 (ru) Растения, устойчивые к гербицидам - ингибиторам hppd
NZ589230A (en) Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means
ATE496127T1 (de) Antisense-modulation der clusterinexpression
ATE453716T1 (de) Verfahren zur modulation der genexpression durch änderung des cpg gehalts
EA200800868A1 (ru) Модуляция экспрессии глюкокортикоидного рецептора
ATE513843T1 (de) Abstellen von genen in vivo durch chemischmodifizierte und stabile sirna
AU2009236219A8 (en) Silencing of CSN5 gene expression using interfering RNA
EA201100813A1 (ru) Фармацевтическая композиция
EA201001393A1 (ru) Липазы с высокой специфичностью к жирным кислотам с короткой цепью и их использование
WO2010017436A3 (en) Modulation of myeloid differentation primary response gene 88 (myd88) expression by antisense oligonucleotides
WO2004033620A3 (en) Methods and compositions for therapeutic use of rna interference
TW200502385A (en) Modulation of forkhead box o1a expression
WO2006081546A3 (en) Inhibitor nucleic acids
PH12013502049A1 (en) Modulation of signal transducer and activator of transcription 3 (stat3) expression
WO2004071407A3 (en) Antisense modulation of ptp1b expression
TNSN08252A1 (en) Sirna anti myosine va et depigmentation de la peau
ATE548454T1 (de) Nukleinsäurewirkstoffe zur stilllegung von h19 zwecks behandlung rheumatoider arthritis
AU2009279857A8 (en) Modulation of toll-like receptor 3 expression by antisense oligonucleotides
IN2014CN03921A (de)
EA201171144A1 (ru) ОПОСРЕДОВАННОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНА ГОМОЛОГА 1 BTB И CNC, ОСНОВНОГО ФАКТОРА ТРАНСКРИПЦИИ С ЛЕЙЦИНОВОЙ МОЛНИЕЙ 1 (Bach1) С ИСПОЛЬЗОВАНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
WO2009105572A3 (en) Antisense modulation of amyloid beta protein expression

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties